Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Trial Profile

REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 21 Sep 2023 Primary endpoint has been met (Percentage of Baseline biomarker-selected population) , according to an Inovio Pharmaceuticals media release.
    • 09 Aug 2023 According to a Inovio Pharmaceuticals media release, based on biomarker data from this study, the company has decided to cease all further development of VGX-3100 as a potential treatment for cervical HSIL in the United States substantial work would be needed to refine this novel biomarker before it could be used in any further Phase 3 trials.
    • 10 May 2023 According to a Inovio Pharmaceuticals media release, analysis of clinical characteristics of biomarker population is ongoing and findings to be shared in third quarter 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top